STEMVAC is administered as maintenance therapy after standard chemo-immunotherapy, and its immunogenicity is assessed by tracking dynamic changes in peripheral CD8+ tumor-infiltrating lymphocytes (TILs), with comparisons made between administration alone and in combination with the adjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF). This evidence concerns the gene CD8A and neoplasm.